|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
US7312318B2
(en)
|
2002-03-01 |
2007-12-25 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
|
US7521220B2
(en)
*
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7527961B2
(en)
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
|
US7425437B2
(en)
*
|
1999-11-26 |
2008-09-16 |
Crucell Holland B.V. |
Vaccines against West Nile Virus
|
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
|
EP1256803A1
(en)
*
|
2001-05-07 |
2002-11-13 |
Crucell Holland B.V. |
Methods for the identification of antiviral compounds
|
|
ATE542904T1
(de)
*
|
2001-10-29 |
2012-02-15 |
Crucell Holland Bv |
Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
|
|
AU2002224199A1
(en)
*
|
2001-10-29 |
2003-06-23 |
Crucell Holland B.V. |
Methods and means for producing proteins with predetermined post-translational modifications
|
|
AU2002225509A1
(en)
*
|
2001-12-07 |
2003-06-17 |
Crucell Holland B.V. |
Production and of viruses, viral isolates and vaccines
|
|
PT1465987E
(pt)
|
2001-12-07 |
2008-04-15 |
Crucell Holland Bv |
Produção de vírus, isolados virais e vacinas
|
|
DK1456238T3
(da)
|
2001-12-17 |
2008-08-18 |
Crucell Holland Bv |
Produktion af F(ab')2-fragmenter i pattedyrceller
|
|
KR100454016B1
(ko)
*
|
2002-01-05 |
2004-10-26 |
한국과학기술원 |
항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
|
|
CN1612747A
(zh)
*
|
2002-01-09 |
2005-05-04 |
克鲁塞尔荷兰公司 |
促红细胞生成素在预防或治疗心力衰竭中的用途
|
|
WO2003068821A2
(en)
|
2002-02-14 |
2003-08-21 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
|
US8287864B2
(en)
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
AU2002307635A1
(en)
*
|
2002-04-19 |
2003-11-03 |
Crucell Holland B.V. |
Methods and means for producing proteins with predetermined post-translational modifications
|
|
ES2524767T3
(es)
|
2002-06-14 |
2014-12-12 |
Immunomedics, Inc. |
Anticuerpo monoclonal humanizado HPAM4
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
DK2314629T4
(da)
|
2002-07-18 |
2023-02-06 |
Merus Nv |
Rekombinant produktion af blandinger af antistoffer
|
|
JP5138867B2
(ja)
|
2002-08-01 |
2013-02-06 |
イミューノメディクス、インコーポレイテッド |
α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法
|
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
|
US8524477B2
(en)
|
2002-10-29 |
2013-09-03 |
Crucell Holland B.V. |
Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
WO2004099396A1
(en)
|
2003-05-09 |
2004-11-18 |
Crucell Holland B.V. |
Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
|
|
AU2004240782B2
(en)
*
|
2003-05-23 |
2011-04-21 |
Crucell Holland B.V. |
Production of recombinant IGM in per.C6 cells
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
EP2322547A1
(en)
|
2003-06-25 |
2011-05-18 |
Crucell Holland B.V. |
Myeloid cell-specific lectin
|
|
CA2534639C
(en)
|
2003-07-31 |
2013-07-30 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
|
EP1508576A1
(en)
*
|
2003-08-20 |
2005-02-23 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
|
CN1863918B
(zh)
|
2003-10-02 |
2011-03-30 |
克鲁塞尔荷兰公司 |
用于重组腺病毒的包装细胞
|
|
WO2005059149A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Chromagenics B.V. |
Improved protein production
|
|
EP1737971B1
(en)
|
2004-01-20 |
2017-08-16 |
Merus N.V. |
Mixtures of binding proteins
|
|
CA2557046A1
(en)
*
|
2004-03-05 |
2005-10-13 |
John Crowley |
Process for cell culturing by continuous perfusion and alternating tangential flow
|
|
EP2314620B1
(en)
|
2004-05-27 |
2013-06-05 |
Crucell Holland B.V. |
Method of identifying binding molecules capable of neutralizing rabies virus
|
|
JP4852046B2
(ja)
|
2004-10-12 |
2012-01-11 |
クルセル ホランド ベー ヴェー |
癌の治療及び検出に用いる結合分子
|
|
KR101271884B1
(ko)
|
2004-11-08 |
2013-06-05 |
크로마제닉스 비.브이. |
고수준으로 단백질을 발현하는 숙주세포의 선택
|
|
US8106170B2
(en)
|
2004-11-11 |
2012-01-31 |
Crucell Holland B.V. |
Compositions against SARS-coronavirus and uses thereof
|
|
CA2591665C
(en)
|
2004-12-20 |
2015-05-05 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing west nile virus and uses thereof
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
WO2006120230A2
(en)
|
2005-05-12 |
2006-11-16 |
Crucell Holland B.V. |
Host cell specific binding molecules capable of neutralizing viruses and uses thereof
|
|
EP1739179A1
(en)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
|
US8470318B2
(en)
|
2005-11-07 |
2013-06-25 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
US20080286819A1
(en)
*
|
2005-11-07 |
2008-11-20 |
Ravetch Jeffrey V |
Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
|
|
US20080206246A1
(en)
*
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
AR053416A1
(es)
|
2005-11-10 |
2007-05-09 |
Protech Pharma S A |
Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
|
|
DE102005054628A1
(de)
|
2005-11-16 |
2007-05-24 |
Cevec Pharmaceuticals Gmbh |
Verfahren zur Herstellung von permanenten humanen Zelllinien
|
|
US7642078B2
(en)
|
2005-12-28 |
2010-01-05 |
Crucell Holland B.V. |
Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
|
|
US7968700B2
(en)
|
2006-03-20 |
2011-06-28 |
Chromagenics B.V. |
Expression augmenting DNA fragments, use thereof, and methods for finding thereof
|
|
CA2647524C
(en)
*
|
2006-04-05 |
2019-11-26 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
MX2008014978A
(es)
|
2006-06-06 |
2008-12-09 |
Crucell Holland Bv |
Moleculas de union humanas que tienen actividad exterminadora contra enterococos y staphylococcus aureus y usos de las mismas.
|
|
CA2881717C
(en)
|
2006-06-06 |
2018-06-12 |
Cecilia Anna Wilhelmina Geuijen |
Human binding molecules having killing activity against staphylococci and uses thereof
|
|
KR101685246B1
(ko)
|
2006-07-14 |
2016-12-09 |
디피엑스 홀딩스 비.브이. |
개선된 세포 배양 방법
|
|
EP2450377A1
(en)
|
2006-09-07 |
2012-05-09 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
|
|
SI2059532T1
(sl)
|
2006-09-07 |
2013-04-30 |
Crucell Holland B.V. |
Humane vezne molekule, ki so zmoĹľne nevtralizirati virus influence H5N1 in njihove uporabe
|
|
JP2010512306A
(ja)
*
|
2006-10-27 |
2010-04-22 |
ザ ロックフェラー ユニバーシティー |
抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
|
|
AU2007317755A1
(en)
*
|
2006-10-27 |
2008-05-15 |
The Rockefeller University |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
US8071332B2
(en)
|
2007-08-10 |
2011-12-06 |
Toto Ltd. |
Recombinant mammal cells, method of producing thereof, and method of producing proteins of interest
|
|
ES2450998T3
(es)
*
|
2007-12-13 |
2014-03-26 |
F. Hoffmann-La Roche Ag |
Nuevas variantes de proteína de cubierta E1 de rubéola y su utilización en la detección de anticuerpos anti-rubéola
|
|
US20120039939A1
(en)
*
|
2008-04-11 |
2012-02-16 |
The Johns Hopkins University |
Compositions and methods for vaccine and virus production
|
|
WO2009132130A2
(en)
|
2008-04-22 |
2009-10-29 |
The Rockefeller University |
Methods of identifying anti-inflammatory compounds
|
|
DK2307538T3
(da)
*
|
2008-07-15 |
2016-01-18 |
Crucell Holland Bv |
Skalérbar fremgangsmåde til dyrkning af per.c6-celler og fremstilling af produkter derfra
|
|
CN102159243B
(zh)
|
2008-07-21 |
2015-08-19 |
免疫医疗公司 |
用于改良的治疗特征的抗体的结构变体
|
|
PL2421895T3
(pl)
|
2009-04-23 |
2016-04-29 |
Crucell Holland Bv |
Rekombinowana ludzka alfa1-antytrypsyna
|
|
CA2761648C
(en)
|
2009-05-11 |
2019-03-12 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
|
|
EP2484761A4
(en)
|
2009-10-01 |
2013-11-27 |
Toto Ltd |
DNA CONSTRUCT AND METHOD FOR PRODUCING RECOMBINANT CHO CELLS THEREWITH
|
|
SMT202600080T1
(it)
|
2010-02-08 |
2026-03-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US8961978B2
(en)
|
2011-07-14 |
2015-02-24 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
|
|
HUE047278T2
(hu)
|
2011-08-05 |
2020-04-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
WO2013093760A2
(en)
|
2011-12-19 |
2013-06-27 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
CN102827273A
(zh)
*
|
2012-02-16 |
2012-12-19 |
张小莺 |
抗痘苗病毒IgY抗体的制备
|
|
SG11201405226TA
(en)
|
2012-03-08 |
2014-11-27 |
Crucell Holland Bv |
Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
|
|
US9248181B2
(en)
|
2012-04-20 |
2016-02-02 |
Merus B.V. |
Methods and means for the production of Ig-like molecules
|
|
US9657290B2
(en)
*
|
2012-07-03 |
2017-05-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Scalable bio-element analysis
|
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
|
HUE042040T2
(hu)
|
2012-09-27 |
2019-06-28 |
Merus Nv |
Bispecifikus IGG antitestek mint T-sejt kapcsolók
|
|
KR20150070181A
(ko)
|
2012-09-27 |
2015-06-24 |
크루셀 홀란드 비.브이. |
B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
|
|
US10196438B2
(en)
|
2013-04-15 |
2019-02-05 |
Janssen Vaccines & Prevention B.V. |
Human antibodies binding to RSV G protein
|
|
EA035846B1
(ru)
|
2013-04-15 |
2020-08-20 |
Янссен Вэксинс Энд Превеншн Б.В. |
Антитела человека, связывающиеся с g-белком rsv
|
|
DE112014003136A5
(de)
|
2013-07-01 |
2016-04-21 |
Charité - Universitätsmedizin Berlin |
Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen
|
|
CN104693308B
(zh)
*
|
2013-12-05 |
2020-08-04 |
同济大学 |
感受胞内pH变化的Smad5蛋白及其应用
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
JP6771385B2
(ja)
|
2014-02-28 |
2020-10-21 |
メルス ナムローゼ フェンノートシャップ |
二重特異性抗体および医薬組成物
|
|
WO2015130173A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibody that binds erbb-2 and erbb-3
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
TWI743024B
(zh)
|
2014-06-06 |
2021-10-21 |
美商健臻公司 |
灌注培養方法及其用途
|
|
WO2016124682A1
(en)
|
2015-02-05 |
2016-08-11 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza neuraminidase
|
|
MY186585A
(en)
|
2015-02-05 |
2021-07-28 |
Janssen Vaccines & Prevention Bv |
Binding molecules directed against influenza hemagglutinin and uses thereof
|
|
WO2016134370A1
(en)
|
2015-02-22 |
2016-08-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Micro-screening apparatus, process, and products
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
US9914777B2
(en)
|
2015-07-10 |
2018-03-13 |
Merus N.V. |
Human CD3 binding antibody
|
|
SMT202100230T1
(it)
|
2015-10-23 |
2021-07-12 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Molecole di legame che inibiscono la crescita tumorale
|
|
WO2017148889A1
(en)
|
2016-03-01 |
2017-09-08 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza b neuraminidase
|
|
WO2018089953A1
(en)
|
2016-11-14 |
2018-05-17 |
Orca Biosystems, Inc. |
Methods and apparatuses for sorting target particles
|
|
CA3056517A1
(en)
|
2017-03-28 |
2018-10-04 |
Janssen Vaccines & Prevention B.V. |
Binding molecules that specifically bind to tau
|
|
IL269656B2
(en)
|
2017-03-31 |
2024-06-01 |
Merus Nv |
Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
|
|
US20200033347A1
(en)
|
2017-04-18 |
2020-01-30 |
Universite Libre De Bruxelles |
Biomarkers And Targets For Proliferative Diseases
|
|
JP7296891B2
(ja)
|
2017-05-17 |
2023-06-23 |
メルス ナムローゼ フェンノートシャップ |
乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
|
|
SG11202001050PA
(en)
|
2017-08-09 |
2020-03-30 |
Merus Nv |
Antibodies that bind egfr and cmet
|
|
JP7230819B2
(ja)
|
2017-10-06 |
2023-03-01 |
小野薬品工業株式会社 |
二重特異性抗体
|
|
KR20200094177A
(ko)
|
2017-12-04 |
2020-08-06 |
얀센 백신스 앤드 프리벤션 비.브이. |
타우에 특이적으로 결합하는 결합 분자
|
|
WO2019149798A1
(en)
|
2018-02-01 |
2019-08-08 |
Janssen Vaccines & Prevention B.V. |
Binding molecules that specifically bind to tau
|
|
TWI890481B
(zh)
|
2018-02-09 |
2025-07-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
IL277307B2
(en)
|
2018-03-23 |
2025-03-01 |
Univ Bruxelles |
Wnt signaling agonist molecules
|
|
TWI862565B
(zh)
|
2019-04-04 |
2024-11-21 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
JP6881658B2
(ja)
|
2019-07-05 |
2021-06-02 |
小野薬品工業株式会社 |
Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
|
|
TW202118790A
(zh)
|
2019-07-30 |
2021-05-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
US20220332825A1
(en)
|
2019-08-08 |
2022-10-20 |
Ono Pharmaceutical Co., Ltd. |
Bispecific protein
|
|
WO2022261348A1
(en)
*
|
2021-06-11 |
2022-12-15 |
Monsanto Technology Llc |
Methods and compositions for altering protein accumulation
|
|
TW202417488A
(zh)
|
2022-08-23 |
2024-05-01 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
WO2026068859A1
(en)
|
2024-09-30 |
2026-04-02 |
Université Libre de Bruxelles |
Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
|